| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 76 | 2023 | 174 | 21.350 |
Why?
|
| Quality of Life | 41 | 2023 | 594 | 7.950 |
Why?
|
| Surveys and Questionnaires | 22 | 2023 | 1085 | 2.920 |
Why?
|
| Severity of Illness Index | 28 | 2020 | 836 | 2.570 |
Why?
|
| Health Status | 11 | 2018 | 214 | 2.420 |
Why?
|
| Patient Reported Outcome Measures | 11 | 2021 | 465 | 2.310 |
Why?
|
| Psychometrics | 16 | 2022 | 216 | 2.310 |
Why?
|
| Adult | 54 | 2022 | 7259 | 1.970 |
Why?
|
| Rheumatology | 6 | 2019 | 77 | 1.910 |
Why?
|
| Body Image | 6 | 2017 | 27 | 1.870 |
Why?
|
| Self Report | 8 | 2023 | 212 | 1.730 |
Why?
|
| Middle Aged | 47 | 2021 | 8303 | 1.720 |
Why?
|
| Female | 64 | 2022 | 14161 | 1.720 |
Why?
|
| Humans | 84 | 2023 | 25165 | 1.650 |
Why?
|
| Reproducibility of Results | 20 | 2022 | 641 | 1.470 |
Why?
|
| Cross-Cultural Comparison | 9 | 2022 | 39 | 1.410 |
Why?
|
| Patient Outcome Assessment | 3 | 2015 | 33 | 1.370 |
Why?
|
| Male | 49 | 2022 | 13815 | 1.350 |
Why?
|
| Hydroxychloroquine | 3 | 2021 | 8 | 1.310 |
Why?
|
| Antirheumatic Agents | 3 | 2021 | 82 | 1.220 |
Why?
|
| Rheumatologists | 2 | 2018 | 14 | 1.170 |
Why?
|
| Cross-Sectional Studies | 14 | 2021 | 852 | 1.020 |
Why?
|
| Pain | 7 | 2020 | 384 | 1.010 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2021 | 8 | 0.990 |
Why?
|
| Fatigue | 4 | 2020 | 47 | 0.920 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2014 | 5 | 0.880 |
Why?
|
| Health Status Indicators | 3 | 2014 | 70 | 0.870 |
Why?
|
| Interferon-alpha | 7 | 2014 | 24 | 0.790 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 6 | 0.770 |
Why?
|
| Depression | 4 | 2020 | 428 | 0.760 |
Why?
|
| Quality of Health Care | 3 | 2023 | 90 | 0.760 |
Why?
|
| Antibodies, Antinuclear | 5 | 2018 | 12 | 0.710 |
Why?
|
| Pain Measurement | 5 | 2019 | 458 | 0.710 |
Why?
|
| Sickness Impact Profile | 4 | 2014 | 9 | 0.710 |
Why?
|
| Lupus Nephritis | 2 | 2017 | 26 | 0.620 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 13 | 0.620 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 16 | 0.610 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 29 | 0.610 |
Why?
|
| Young Adult | 12 | 2020 | 1813 | 0.590 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 121 | 0.580 |
Why?
|
| Cost of Illness | 2 | 2015 | 48 | 0.570 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 118 | 0.570 |
Why?
|
| Factor Analysis, Statistical | 7 | 2020 | 54 | 0.560 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 21 | 0.550 |
Why?
|
| Adolescent | 11 | 2020 | 2018 | 0.550 |
Why?
|
| Culture | 2 | 2013 | 23 | 0.530 |
Why?
|
| Physicians | 3 | 2015 | 113 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 105 | 0.510 |
Why?
|
| Canada | 4 | 2018 | 46 | 0.510 |
Why?
|
| Biological Products | 1 | 2016 | 34 | 0.500 |
Why?
|
| Language | 6 | 2022 | 61 | 0.500 |
Why?
|
| Linear Models | 6 | 2018 | 238 | 0.480 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2019 | 251 | 0.470 |
Why?
|
| United States | 7 | 2018 | 1928 | 0.470 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 2 | 0.460 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 2 | 0.460 |
Why?
|
| Interleukin-10 | 1 | 2014 | 18 | 0.450 |
Why?
|
| Interleukin-6 | 1 | 2014 | 73 | 0.440 |
Why?
|
| Treatment Outcome | 10 | 2018 | 3204 | 0.440 |
Why?
|
| Autoantibodies | 8 | 2013 | 77 | 0.440 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 122 | 0.440 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 7 | 0.430 |
Why?
|
| Teaching | 2 | 2019 | 48 | 0.420 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 18 | 0.410 |
Why?
|
| Dermatology | 1 | 2012 | 6 | 0.410 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 13 | 0.410 |
Why?
|
| Hospitals, County | 1 | 2012 | 4 | 0.400 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1301 | 0.400 |
Why?
|
| Hospitals, University | 1 | 2012 | 22 | 0.400 |
Why?
|
| Caregivers | 1 | 2015 | 188 | 0.400 |
Why?
|
| Adaptation, Psychological | 5 | 2016 | 172 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2017 | 266 | 0.390 |
Why?
|
| Emotions | 3 | 2017 | 69 | 0.390 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2011 | 2 | 0.390 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 3 | 0.370 |
Why?
|
| Aged | 10 | 2021 | 8448 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2018 | 370 | 0.350 |
Why?
|
| Benchmarking | 1 | 2010 | 30 | 0.340 |
Why?
|
| Demography | 1 | 2010 | 67 | 0.330 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 199 | 0.330 |
Why?
|
| Income | 1 | 2010 | 77 | 0.330 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 1005 | 0.330 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 450 | 0.310 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 571 | 0.310 |
Why?
|
| Case-Control Studies | 6 | 2014 | 557 | 0.310 |
Why?
|
| Stress, Psychological | 3 | 2020 | 229 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 275 | 0.300 |
Why?
|
| Paracentesis | 1 | 2007 | 3 | 0.280 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2007 | 2 | 0.280 |
Why?
|
| Suction | 1 | 2007 | 40 | 0.280 |
Why?
|
| Tattooing | 1 | 2007 | 2 | 0.280 |
Why?
|
| Genital Diseases, Female | 1 | 2006 | 5 | 0.270 |
Why?
|
| Reference Values | 3 | 2014 | 182 | 0.270 |
Why?
|
| Chronic Disease | 2 | 2005 | 397 | 0.270 |
Why?
|
| Hyperuricemia | 1 | 2006 | 2 | 0.260 |
Why?
|
| Takayasu Arteritis | 1 | 2005 | 1 | 0.250 |
Why?
|
| Chicago | 2 | 2018 | 916 | 0.250 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 54 | 0.250 |
Why?
|
| Uveitis | 1 | 2005 | 10 | 0.250 |
Why?
|
| Vasculitis | 1 | 2005 | 25 | 0.240 |
Why?
|
| Prognosis | 3 | 2014 | 693 | 0.240 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 5 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 154 | 0.230 |
Why?
|
| Heart Diseases | 1 | 2005 | 53 | 0.230 |
Why?
|
| Chlamydia trachomatis | 1 | 2004 | 6 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 184 | 0.230 |
Why?
|
| Chlamydia Infections | 1 | 2004 | 7 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 42 | 0.230 |
Why?
|
| Depressive Disorder | 2 | 2018 | 174 | 0.220 |
Why?
|
| Translations | 2 | 2013 | 9 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 318 | 0.210 |
Why?
|
| Comorbidity | 3 | 2013 | 458 | 0.210 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 301 | 0.200 |
Why?
|
| Sex Factors | 2 | 2018 | 430 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 72 | 0.200 |
Why?
|
| Vaccination | 1 | 2021 | 30 | 0.190 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 41 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2020 | 1618 | 0.190 |
Why?
|
| Regression Analysis | 3 | 2020 | 251 | 0.180 |
Why?
|
| Autoimmunity | 2 | 2010 | 12 | 0.170 |
Why?
|
| Health Surveys | 2 | 2017 | 82 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2017 | 1772 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 318 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 305 | 0.160 |
Why?
|
| Age Factors | 3 | 2016 | 712 | 0.160 |
Why?
|
| Azacitidine | 1 | 2019 | 8 | 0.160 |
Why?
|
| Asia | 1 | 2018 | 8 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 110 | 0.160 |
Why?
|
| Europe | 1 | 2018 | 53 | 0.160 |
Why?
|
| Mentors | 1 | 2019 | 32 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 12 | 0.160 |
Why?
|
| Morbidity | 1 | 2018 | 50 | 0.150 |
Why?
|
| Arthritis, Experimental | 1 | 2019 | 46 | 0.150 |
Why?
|
| Workload | 1 | 2018 | 25 | 0.150 |
Why?
|
| Patient Acuity | 1 | 2018 | 5 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2018 | 78 | 0.150 |
Why?
|
| Phenotype | 4 | 2012 | 286 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2019 | 40 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2019 | 50 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2014 | 578 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 301 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2020 | 390 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 151 | 0.140 |
Why?
|
| Interferon Type I | 2 | 2017 | 9 | 0.140 |
Why?
|
| Genome-Wide Association Study | 4 | 2012 | 267 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3185 | 0.140 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 53 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2017 | 58 | 0.140 |
Why?
|
| Philippines | 2 | 2017 | 4 | 0.140 |
Why?
|
| CD11b Antigen | 1 | 2017 | 14 | 0.140 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 14 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 231 | 0.130 |
Why?
|
| Macrophages | 1 | 2017 | 87 | 0.130 |
Why?
|
| Mental Health | 1 | 2017 | 104 | 0.130 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 294 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 1336 | 0.130 |
Why?
|
| France | 1 | 2016 | 11 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 70 | 0.130 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 105 | 0.130 |
Why?
|
| Arthralgia | 2 | 2008 | 125 | 0.130 |
Why?
|
| Software | 1 | 2015 | 58 | 0.120 |
Why?
|
| Hong Kong | 1 | 2015 | 1 | 0.120 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2017 | 4 | 0.120 |
Why?
|
| Self Concept | 2 | 2012 | 36 | 0.120 |
Why?
|
| Sleep | 1 | 2017 | 290 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cosmetic Techniques | 1 | 2014 | 4 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2016 | 389 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2014 | 17 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 20 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 319 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 126 | 0.120 |
Why?
|
| Focus Groups | 1 | 2014 | 82 | 0.110 |
Why?
|
| Goals | 1 | 2014 | 38 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 273 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2011 | 92 | 0.110 |
Why?
|
| Interferon Regulatory Factors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Turkey | 1 | 2013 | 5 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 87 | 0.110 |
Why?
|
| Latin America | 1 | 2013 | 5 | 0.110 |
Why?
|
| Disease Management | 1 | 2013 | 89 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2013 | 128 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 77 | 0.100 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 28 | 0.100 |
Why?
|
| Self-Assessment | 1 | 2012 | 29 | 0.100 |
Why?
|
| Feedback | 1 | 2012 | 30 | 0.100 |
Why?
|
| Osteopontin | 1 | 2011 | 5 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2011 | 5 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 450 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 133 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 4508 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 4 | 0.090 |
Why?
|
| Complementary Therapies | 1 | 2011 | 7 | 0.090 |
Why?
|
| DNA | 4 | 2013 | 103 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 79 | 0.090 |
Why?
|
| Alleles | 4 | 2011 | 211 | 0.090 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2010 | 39 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 42 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 567 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 38 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 42 | 0.080 |
Why?
|
| United Kingdom | 1 | 2010 | 39 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1672 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 84 | 0.080 |
Why?
|
| Social Environment | 1 | 2010 | 73 | 0.080 |
Why?
|
| Animals | 3 | 2019 | 3430 | 0.080 |
Why?
|
| Self-Examination | 1 | 2009 | 3 | 0.080 |
Why?
|
| California | 3 | 2017 | 34 | 0.080 |
Why?
|
| Cytokines | 1 | 2010 | 203 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 273 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1032 | 0.080 |
Why?
|
| Biomarkers | 1 | 2011 | 520 | 0.080 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 17 | 0.070 |
Why?
|
| Prevalence | 2 | 2011 | 428 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 287 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2007 | 50 | 0.070 |
Why?
|
| Vulva | 1 | 2006 | 1 | 0.070 |
Why?
|
| Data Collection | 1 | 2007 | 87 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2007 | 32 | 0.070 |
Why?
|
| Injections, Intra-Articular | 1 | 2007 | 90 | 0.070 |
Why?
|
| Joints | 1 | 2007 | 63 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cognition | 1 | 2014 | 1270 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2020 | 252 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 17 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 83 | 0.060 |
Why?
|
| Genotype | 3 | 2011 | 338 | 0.060 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 41 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 15 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Lactones | 1 | 2004 | 9 | 0.060 |
Why?
|
| Sulfones | 1 | 2004 | 20 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 16 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2007 | 171 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 32 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 126 | 0.060 |
Why?
|
| Mice | 2 | 2019 | 1300 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 153 | 0.060 |
Why?
|
| Synovial Fluid | 1 | 2004 | 90 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 334 | 0.050 |
Why?
|
| Pregnancy | 1 | 2004 | 298 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 103 | 0.050 |
Why?
|
| Hypertension | 1 | 2004 | 177 | 0.050 |
Why?
|
| Prostaglandins A | 1 | 2022 | 1 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ribonucleoproteins | 2 | 2011 | 3 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 348 | 0.050 |
Why?
|
| Cell Line | 2 | 2012 | 251 | 0.050 |
Why?
|
| Egypt | 1 | 2020 | 1 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 59 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2019 | 21 | 0.040 |
Why?
|
| Anxiety | 1 | 2020 | 150 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 99 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 50 | 0.040 |
Why?
|
| Malaria | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 11 | 0.040 |
Why?
|
| Complement C1q | 1 | 2018 | 9 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2018 | 64 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 77 | 0.040 |
Why?
|
| Georgia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2017 | 13 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2017 | 2 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 5 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 32 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 64 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 49 | 0.030 |
Why?
|
| Child | 1 | 2020 | 1211 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 173 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2016 | 119 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 2179 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 5 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 25 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 16 | 0.020 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2011 | 26 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2010 | 1 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 8 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 22 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 5 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 23 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 54 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2010 | 48 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 79 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 113 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 116 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 59 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 401 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 252 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 250 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 338 | 0.020 |
Why?
|
| Knee Joint | 1 | 2008 | 662 | 0.010 |
Why?
|